 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of high-dose IL-2 combined with stereotactic ablation radiotherapy in the treatment of metastatic renal cell carcinoma

Clin Cancer Res: Efficacy of high-dose IL-2 combined with stereotactic ablation radiotherapy in the treatment of metastatic renal cell carcinoma

 Last Update: 2021-12-03
 Source: Internet
 Author: User

Tags

termite treatment product

lethal dose potassium

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Up to 30% of renal cell carcinoma (RCC) patients have developed distant metastases at the time of diagnosis, and about 20% of local RCC patients will subsequently develop metastases
.

In immune -based regimens have been used in the treatment of metastatic renal cell carcinoma

immunity

This is a phase II clinical trial to evaluate whether additional stereotactic ablation radiotherapy (SAbR) can promote tumor antigen presentation and improve the overall response rate of patients with metastatic renal cell carcinoma to high-dose IL2 (HR IL2)
.

Recruited patients with clear cell renal cell carcinoma diagnosed pathologically and metastasized by imaging and were treated with SAbR, followed by HD IL2
.

The primary endpoint is the overall response rate (ORR)

Overall survival rate and progression-free survival rate

A total of 30 patients with metastatic renal cell carcinoma of different ethnicities were recruited, and the median number of metastases treated with SAbR was two
.

Among the 25 evaluable (RECISTv1.

The overall remission rate was 16%, and the complete remission rate reached 8%

Treatment-related adverse events

A total of 22 treatment-related adverse events (AE) of grade 3 and above occurred, and there was no difference with HD IL2 alone
.

No grade 5 AE event occurred

A total of 22 treatment-related adverse events (AE) of grade 3 and above occurred, and there was no difference with HD IL2 alone

The addition of SAbR does not improve the response rate of patients with metastatic renal cell carcinoma to high-dose IL2

Original source:

Raquibul Hannan, et al.

Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma In this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.